| 000 | 01793 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516173955.0 | ||
| 264 | 0 | _c20140831 | |
| 008 | 201408s 0 0 eng d | ||
| 022 | _a1873-2763 | ||
| 024 | 7 |
_a10.1016/j.bone.2013.10.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLescaille, Géraldine | |
| 245 | 0 | 0 |
_aClinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. _h[electronic resource] |
| 260 |
_bBone _cJan 2014 |
||
| 300 |
_a103-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xdrug therapy |
| 650 | 0 | 4 |
_aDiphosphonates _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadverse effects |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aCoudert, Amélie E | |
| 700 | 1 | _aBaaroun, Vanessa | |
| 700 | 1 | _aOstertag, Agnès | |
| 700 | 1 | _aCharpentier, Emmanuel | |
| 700 | 1 | _aJavelot, Marie-José | |
| 700 | 1 | _aTolédo, Rafael | |
| 700 | 1 | _aGoudot, Patrick | |
| 700 | 1 | _aAzérad, Jean | |
| 700 | 1 | _aBerdal, Ariane | |
| 700 | 1 | _aSpano, Jean-Philippe | |
| 700 | 1 | _aRuhin, Blandine | |
| 700 | 1 | _aDescroix, Vianney | |
| 773 | 0 |
_tBone _gvol. 58 _gp. 103-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bone.2013.10.002 _zAvailable from publisher's website |
| 999 |
_c23166150 _d23166150 |
||